What is the current market valuation of the induced pluripotent-stem-cells market in the UK?

The market valuation was $239.5 Million in 2024. Read More

What is the projected market size for the induced pluripotent-stem-cells market by 2035?

The projected market size is $624.9 Million by 2035. Read More

What is the expected CAGR for the induced pluripotent-stem-cells market during the forecast period 2025 - 2035?

The expected CAGR is 9.11% during the forecast period 2025 - 2035. Read More

Which application segments are expected to drive growth in the induced pluripotent-stem-cells market?

Key application segments include Drug Discovery, projected to grow from $60.0 Million to $180.0 Million. Read More

What are the leading cell types in the induced pluripotent-stem-cells market?

Mesenchymal Stem Cells lead the market, with a valuation range from $124.5 Million to $334.9 Million. Read More

Which sources of induction are anticipated to contribute significantly to market growth?

Viral Vectors are expected to be significant, with a valuation range from $99.5 Million to $244.9 Million. Read More

Who are the key players in the induced pluripotent-stem-cells market?

Key players include Fujifilm Cellular Dynamics, Inc., Astellas Pharma Inc., and Roche Holding AG. Read More

What role do pharmaceutical companies play in the induced pluripotent-stem-cells market?

Pharmaceutical Companies are projected to contribute between $95.0 Million and $250.0 Million. Read More

How do research institutes impact the induced pluripotent-stem-cells market?

Research Institutes are expected to generate revenues between $60.0 Million and $160.0 Million. Read More

What trends are emerging in the induced pluripotent-stem-cells market in the UK?

Emerging trends include increased investment in regenerative medicine and advancements in gene therapy. Read More

UK Induced Pluripotent Stem Cells Market

ID: MRFR/LS/50680-HCR

200 Pages

Nidhi Mandole

Last Updated: February 06, 2026

UK Induced Pluripotent Stem Cells Market Research Report: Size, Share, Trend Analysis By Applications (Regenerative Medicine, Drug Discovery, Disease Modeling, Toxicology Testing, Gene Therapy), By Cell Type (Cardiomyocytes, Neurons, Hepatocytes, Pancreatic Cells, Mesenchymal Stem Cells), By Source of Induction (Transcription Factors, Small Molecules, MicroRNA, Electroporation, Viral Vectors) and By End Users (Pharmaceutical Companies, Research Institutes, Biotechnology Companies, Academic Institutions) - Growth Outlook & Industry Forecast 2025 To 2035

UK Induced Pluripotent Stem Cells Market

Market Size

Forecast Period2025 - 2035

CAGR (2025 - 2035)9.11%

2024 Market Size$ 239.5 Million

2025 Market Size$ 261.32 Million

2035 Market Size$ 624.9 Million

Key Players

Fujifilm Cellular Dynamics

Inc.

Astellas Pharma Inc.

Takeda Pharmaceutical Company Limited

Roche Holding AG

Lonza Group AG

Trends

Increased Investment in Research and Development
Expansion of Clinical Applications
Regulatory Support and Frameworks

Opportunities

Advancements in Stem Cell Technologies
Rising Prevalence of Genetic Disorders
Growing Demand for Regenerative Medicine

Summary Table of Contents Segmentation Download PDF

Certified Researchers

Customize Report

1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
1. 1.1 EXECUTIVE SUMMARY
  1. 1.1.1 Market Overview
  2. 1.1.2 Key Findings
  3. 1.1.3 Market Segmentation
  4. 1.1.4 Competitive Landscape
  5. 1.1.5 Challenges and Opportunities
  6. 1.1.6 Future Outlook
2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
1. 2.1 MARKET INTRODUCTION
  1. 2.1.1 Definition
  2. 2.1.2 Scope of the study
    1. 2.1.2.1 Research Objective
    2. 2.1.2.2 Assumption
    3. 2.1.2.3 Limitations
2. 2.2 RESEARCH METHODOLOGY
  1. 2.2.1 Overview
  2. 2.2.2 Data Mining
  3. 2.2.3 Secondary Research
  4. 2.2.4 Primary Research
    1. 2.2.4.1 Primary Interviews and Information Gathering Process
    2. 2.2.4.2 Breakdown of Primary Respondents
  5. 2.2.5 Forecasting Model
  6. 2.2.6 Market Size Estimation
    1. 2.2.6.1 Bottom-Up Approach
    2. 2.2.6.2 Top-Down Approach
  7. 2.2.7 Data Triangulation
  8. 2.2.8 Validation
3 SECTION III: QUALITATIVE ANALYSIS
1. 3.1 MARKET DYNAMICS
  1. 3.1.1 Overview
  2. 3.1.2 Drivers
  3. 3.1.3 Restraints
  4. 3.1.4 Opportunities
2. 3.2 MARKET FACTOR ANALYSIS
  1. 3.2.1 Value chain Analysis
  2. 3.2.2 Porter's Five Forces Analysis
    1. 3.2.2.1 Bargaining Power of Suppliers
    2. 3.2.2.2 Bargaining Power of Buyers
    3. 3.2.2.3 Threat of New Entrants
    4. 3.2.2.4 Threat of Substitutes
    5. 3.2.2.5 Intensity of Rivalry
  3. 3.2.3 COVID-19 Impact Analysis
    1. 3.2.3.1 Market Impact Analysis
    2. 3.2.3.2 Regional Impact
    3. 3.2.3.3 Opportunity and Threat Analysis
4 SECTION IV: QUANTITATIVE ANALYSIS
1. 4.1 Construction, BY Application (USD Million)
  1. 4.1.1 Regenerative Medicine
  2. 4.1.2 Drug Discovery
  3. 4.1.3 Disease Modeling
  4. 4.1.4 Toxicology Testing
  5. 4.1.5 Gene Therapy
2. 4.2 Construction, BY Cell Type (USD Million)
  1. 4.2.1 Cardiomyocytes
  2. 4.2.2 Neurons
  3. 4.2.3 Hepatocytes
  4. 4.2.4 Pancreatic Cells
  5. 4.2.5 Mesenchymal Stem Cells
3. 4.3 Construction, BY Source of Induction (USD Million)
  1. 4.3.1 Transcription Factors
  2. 4.3.2 Small Molecules
  3. 4.3.3 MicroRNA
  4. 4.3.4 Electroporation
  5. 4.3.5 Viral Vectors
4. 4.4 Construction, BY End User (USD Million)
  1. 4.4.1 Pharmaceutical Companies
  2. 4.4.2 Research Institutes
  3. 4.4.3 Biotechnology Companies
  4. 4.4.4 Academic Institutions
5 SECTION V: COMPETITIVE ANALYSIS
1. 5.1 Competitive Landscape
  1. 5.1.1 Overview
  2. 5.1.2 Competitive Analysis
  3. 5.1.3 Market share Analysis
  4. 5.1.4 Major Growth Strategy in the Construction
  5. 5.1.5 Competitive Benchmarking
  6. 5.1.6 Leading Players in Terms of Number of Developments in the Construction
  7. 5.1.7 Key developments and growth strategies
    1. 5.1.7.1 New Product Launch/Service Deployment
    2. 5.1.7.2 Merger & Acquisitions
    3. 5.1.7.3 Joint Ventures
  8. 5.1.8 Major Players Financial Matrix
    1. 5.1.8.1 Sales and Operating Income
    2. 5.1.8.2 Major Players R&D Expenditure. 2023
2. 5.2 Company Profiles
  1. 5.2.1 Fujifilm Cellular Dynamics, Inc. (US)
    1. 5.2.1.1 Financial Overview
    2. 5.2.1.2 Products Offered
    3. 5.2.1.3 Key Developments
    4. 5.2.1.4 SWOT Analysis
    5. 5.2.1.5 Key Strategies
  2. 5.2.2 Astellas Pharma Inc. (JP)
    1. 5.2.2.1 Financial Overview
    2. 5.2.2.2 Products Offered
    3. 5.2.2.3 Key Developments
    4. 5.2.2.4 SWOT Analysis
    5. 5.2.2.5 Key Strategies
  3. 5.2.3 Takeda Pharmaceutical Company Limited (JP)
    1. 5.2.3.1 Financial Overview
    2. 5.2.3.2 Products Offered
    3. 5.2.3.3 Key Developments
    4. 5.2.3.4 SWOT Analysis
    5. 5.2.3.5 Key Strategies
  4. 5.2.4 Roche Holding AG (CH)
    1. 5.2.4.1 Financial Overview
    2. 5.2.4.2 Products Offered
    3. 5.2.4.3 Key Developments
    4. 5.2.4.4 SWOT Analysis
    5. 5.2.4.5 Key Strategies
  5. 5.2.5 Lonza Group AG (CH)
    1. 5.2.5.1 Financial Overview
    2. 5.2.5.2 Products Offered
    3. 5.2.5.3 Key Developments
    4. 5.2.5.4 SWOT Analysis
    5. 5.2.5.5 Key Strategies
  6. 5.2.6 Cellectis S.A. (FR)
    1. 5.2.6.1 Financial Overview
    2. 5.2.6.2 Products Offered
    3. 5.2.6.3 Key Developments
    4. 5.2.6.4 SWOT Analysis
    5. 5.2.6.5 Key Strategies
  7. 5.2.7 Regenative Labs, LLC (US)
    1. 5.2.7.1 Financial Overview
    2. 5.2.7.2 Products Offered
    3. 5.2.7.3 Key Developments
    4. 5.2.7.4 SWOT Analysis
    5. 5.2.7.5 Key Strategies
  8. 5.2.8 Cellular Biomedicine Group, Inc. (US)
    1. 5.2.8.1 Financial Overview
    2. 5.2.8.2 Products Offered
    3. 5.2.8.3 Key Developments
    4. 5.2.8.4 SWOT Analysis
    5. 5.2.8.5 Key Strategies
3. 5.3 Appendix
  1. 5.3.1 References
  2. 5.3.2 Related Reports
6 LIST OF FIGURES
1. 6.1 MARKET SYNOPSIS
2. 6.2 UK MARKET ANALYSIS BY APPLICATION
3. 6.3 UK MARKET ANALYSIS BY CELL TYPE
4. 6.4 UK MARKET ANALYSIS BY SOURCE OF INDUCTION
5. 6.5 UK MARKET ANALYSIS BY END USER
6. 6.6 KEY BUYING CRITERIA OF CONSTRUCTION
7. 6.7 RESEARCH PROCESS OF MRFR
8. 6.8 DRO ANALYSIS OF CONSTRUCTION
9. 6.9 DRIVERS IMPACT ANALYSIS: CONSTRUCTION
10. 6.10 RESTRAINTS IMPACT ANALYSIS: CONSTRUCTION
11. 6.11 SUPPLY / VALUE CHAIN: CONSTRUCTION
12. 6.12 CONSTRUCTION, BY APPLICATION, 2024 (% SHARE)
13. 6.13 CONSTRUCTION, BY APPLICATION, 2024 TO 2035 (USD Million)
14. 6.14 CONSTRUCTION, BY CELL TYPE, 2024 (% SHARE)
15. 6.15 CONSTRUCTION, BY CELL TYPE, 2024 TO 2035 (USD Million)
16. 6.16 CONSTRUCTION, BY SOURCE OF INDUCTION, 2024 (% SHARE)
17. 6.17 CONSTRUCTION, BY SOURCE OF INDUCTION, 2024 TO 2035 (USD Million)
18. 6.18 CONSTRUCTION, BY END USER, 2024 (% SHARE)
19. 6.19 CONSTRUCTION, BY END USER, 2024 TO 2035 (USD Million)
20. 6.20 BENCHMARKING OF MAJOR COMPETITORS
7 LIST OF TABLES
1. 7.1 LIST OF ASSUMPTIONS
7.1.1
1. 7.2 UK MARKET SIZE ESTIMATES; FORECAST
  1. 7.2.1 BY APPLICATION, 2025-2035 (USD Million)
  2. 7.2.2 BY CELL TYPE, 2025-2035 (USD Million)
  3. 7.2.3 BY SOURCE OF INDUCTION, 2025-2035 (USD Million)
  4. 7.2.4 BY END USER, 2025-2035 (USD Million)
2. 7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
7.3.1
1. 7.4 ACQUISITION/PARTNERSHIP
7.4.1

Certified Researchers

Customize Report

UK Construction Market Segmentation

Construction By Application (USD Million, 2025-2035)

Regenerative Medicine
Drug Discovery
Disease Modeling
Toxicology Testing
Gene Therapy

Construction By Cell Type (USD Million, 2025-2035)

Cardiomyocytes
Neurons
Hepatocytes
Pancreatic Cells
Mesenchymal Stem Cells

Construction By Source of Induction (USD Million, 2025-2035)

Transcription Factors
Small Molecules
MicroRNA
Electroporation
Viral Vectors

Construction By End User (USD Million, 2025-2035)

Pharmaceutical Companies
Research Institutes
Biotechnology Companies
Academic Institutions

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”